These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 25934099)

  • 21. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.
    de Borst MH; Vervloet MG; ter Wee PM; Navis G
    J Am Soc Nephrol; 2011 Sep; 22(9):1603-9. PubMed ID: 21852584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative idiosyncrasies in life extension by reduced mTOR signalling and its distinctiveness from dietary restriction.
    Garratt M; Nakagawa S; Simons MJ
    Aging Cell; 2016 Aug; 15(4):737-43. PubMed ID: 27139919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTORC1 and SIRT1 Cooperate to Foster Expansion of Gut Adult Stem Cells during Calorie Restriction.
    Igarashi M; Guarente L
    Cell; 2016 Jul; 166(2):436-450. PubMed ID: 27345368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTORC2-SGK-1 acts in two environmentally responsive pathways with opposing effects on longevity.
    Mizunuma M; Neumann-Haefelin E; Moroz N; Li Y; Blackwell TK
    Aging Cell; 2014 Oct; 13(5):869-78. PubMed ID: 25040785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AMPK as a Pro-longevity Target.
    Burkewitz K; Weir HJ; Mair WB
    Exp Suppl; 2016; 107():227-256. PubMed ID: 27812983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caloric restriction and its mimetics.
    Lee SH; Min KJ
    BMB Rep; 2013 Apr; 46(4):181-7. PubMed ID: 23615258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coming of age: molecular drivers of aging and therapeutic opportunities.
    Newgard CB; Sharpless NE
    J Clin Invest; 2013 Mar; 123(3):946-50. PubMed ID: 23454756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
    Arriola Apelo SI; Lamming DW
    J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary restriction, mitochondrial function and aging: from yeast to humans.
    Ruetenik A; Barrientos A
    Biochim Biophys Acta; 2015 Nov; 1847(11):1434-47. PubMed ID: 25979234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.
    Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C
    Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.
    Prié D; Friedlander G
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1717-22. PubMed ID: 20798257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of metabolic health and aging by nutrient-sensitive signaling pathways.
    Cummings NE; Lamming DW
    Mol Cell Endocrinol; 2017 Nov; 455():13-22. PubMed ID: 27884780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next Generation Strategies for Geroprotection via mTORC1 Inhibition.
    Dumas SN; Lamming DW
    J Gerontol A Biol Sci Med Sci; 2020 Jan; 75(1):14-23. PubMed ID: 30794726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae.
    Medvedik O; Lamming DW; Kim KD; Sinclair DA
    PLoS Biol; 2007 Oct; 5(10):e261. PubMed ID: 17914901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic modeling of signal transduction by mTOR complexes in cancer.
    Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
    J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Insights Into the Role of mTOR Signaling in the Cardiovascular System.
    Sciarretta S; Forte M; Frati G; Sadoshima J
    Circ Res; 2018 Feb; 122(3):489-505. PubMed ID: 29420210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptation to chronic mTOR inhibition in cancer and in aging.
    Gilley R; Balmanno K; Cope CL; Cook SJ
    Biochem Soc Trans; 2013 Aug; 41(4):956-61. PubMed ID: 23863163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.